title: Strain dependent protection conferred by Lactobacillus spp. administered orally with a Salmonella Typhimurium vaccine in a murine challenge model.
abstract: Consumption of Lactobacillus spp. has been shown to enhance immune responses in mice. This study examined the immuno-adjuvant capacity of two strains: Lactobacillus acidophilus L10 and Lactobacillus fermentum PC2, in the induction of protective humoral immunity in a Salmonella Typhimurium vaccine challenge model. Briefly, BALB/c mice were divided into four groups. Three groups of mice received S. Typhimurium vaccine (10(8) colony forming units (CFU) per dose) on days 0 and 14. In addition to the vaccine, five doses (10(8) CFU per dose) of either L. acidophilus L10 or L. fermentum PC2 were also administered to a group. All mice were challenged with viable S. Typhimurium on day 28. On day 10 post challenge, the study was terminated and microbial and immunological parameters were assessed. Mice dosed with L. fermentum PC2 in addition to the vaccine had a significantly enhanced S. Typhimurium humoral response. The mice in this group had high levels of lactobacilli in the feces and in association with the Peyer's patches, no detectable levels of either lactobacilli or S. Typhimurium in the spleen, and no detectable weight loss. Mice given L. acidophilus L10 with the vaccine were unable to exhibit elevated S. Typhimurium specific humoral responses. However, there was no detectable S. Typhimurium in the spleens of this group. Interestingly, translocation of lactobacilli into the spleen was observed as well as a slight weight loss was noted in mice that received the L. acidophilus L10 with the vaccine. This study shows that, the L. fermentum PC2 had a greater capacity than the L. acidophilus L10 to act as an oral adjuvant in a S. Typhimurium oral vaccine program and afforded greater protection against a live S. Typhimurium challenge.
authors.affiliation: Centre for Marine Bioinnovation, The University of New South Wales, Sydney, NSW 2052, Australia.
authors.forename: M
authors.initials: M
authors.lastname: Esvaran
authors.forename: P L
authors.initials: PL
authors.lastname: Conway
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000284:Administration, Oral; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D005260:Female; D006801:Humans; D056724:Immunity, Humoral / Q000187:drug effects; D007779:Lactobacillus acidophilus / Q000276:immunology; D052197:Limosilactobacillus fermentum / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D019936:Probiotics / Q000008:administration & dosage*; D012480:Salmonella Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D022562:Salmonella Vaccines / Q000276:immunology*; D012486:Salmonella typhimurium / Q000187:drug effects / Q000276:immunology*; D013045:Species Specificity; D013154:Spleen / Q000187:drug effects / Q000276:immunology / Q000382:microbiology
chemical_list: D000276:Adjuvants, Immunologic; D022562:Salmonella Vaccines